All In Biotech

Drug Trial Radar · NCT05817240

A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

A Phase 1, Single-Center, Fixed Sequence, Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Dec 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

May 3, 2023

Primary completion

Jun 11, 2023

Study completion Jun 21, 2023

Sponsor

Lead sponsor
Endeavor Biomedicines, Inc.Industry
Sponsor type
Industry
First posted
Apr 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about the potential effect of ENV-101 (taladegib) on the pharmacokinetics of nintedanib (an approved treatment for idiopathic pulmonary fibrosis) when the two compounds are dosed together in healthy subjects. Participants in this study will receive ENV-101 and/or nintedanib on various days throughout a 10-day period during which they will reside at the clinical trial site.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • taladegibDrug

    100 mg per tablet, dosed once daily

  • nintedanibDrug

    100 mg per capsule, dosed once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Nintedanib maximum blood concentration (Cmax) after administration alone and after coadministration with ENV-101 (taladegib)Time frame: Day 1 and Day 7
  2. Time of nintedanib maximum blood concentration (Tmax) after coadministration alone and after coadministration with ENV-101 (taladegib)Time frame: Day 1 and Day 7
  3. Nintedanib absorption to time t (AUC0-t) after administration alone and after coadministration with ENV-101 (taladegib)Time frame: Day 1 and Day 7
  4. Nintedanib total absorption (AUC0-inf) after administration alone and after coadministration with ENV-101 (taladegib)Time frame: Day 1 and Day 7
  5. Nintedanib half-life in the blood (T1/2) after administration alone and after coadministration with ENV-101 (taladegib)Time frame: Day 1 and Day 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.